3 results
Primary Objective:To induce clinical response (CDAI decrease from baseline * 100 points) and/or remission(CDAI <150) following 12 weeks of treatment with one of two active doses ofGSK1605786A for qualification of subjects for enrolment into a…
The primary objective of this study is:- To evaluate the effect of the elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single-tablet regimen (STR) on renal parameters at Week 24The secondary objectives of this study are:- To…
To demonstrate superiority of the NEURO TRONIC SC-KAFO in stance control securing while walking under challenging conditions compared to the E-MAG Active SC-KAFO; and to demonstrate superiority of the NEURO TRONIC SC-KAFO on walking energy cost,…